Pharmaceutical Technology4 天
CM-24 by Purple Biotech for Ovarian Cancer: Likelihood of Approval
CM-24 is under clinical development by Purple Biotech and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success rate ...